$ODC

Oil-Dri Corporation Of America (NYSE:ODC) Rating Lowered to "Hold" at Wall Street Zen

Wall Street Zen has downgraded Oil-Dri Corporation Of America (NYSE:ODC) from "strong-buy" to "hold" despite other analysts maintaining "buy" ratings. This comes after the specialty chemicals company reported a steep drop in quarterly EPS and recent insider stock sales by two VPs in October. The company's financials show a market cap of $740.86 million and a P/E ratio of 13.90.

Original reporting
MarketBeat · MarketBeat
Published Dec 13, 2025, 7:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Dec 13, 2025, 8:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oil-Dri Corporation Of America (NYSE:ODC) Rating Lowered to "Hold" at Wall Street Zen — source image
Decision brief

The 30-second read

$ODCNeutralMed
01

Why it matters

The rating change reflects increased short-term risk, likely leading to decreased stock price and investor caution.

02

Market read

The news is relevant for traders with exposure to ODC or the chemicals sector, indicating a need for risk reassessment.

03

What to watch

Potential for operational improvements or strategic initiatives that could offset recent earnings decline; macroeconomic factors favoring chemicals sector may support recovery

Timing: Immediate to short-term

Background

Oil-Dri Corporation of America reported a significant EPS decline and insider sales, prompting a rating downgrade from 'strong-buy' to 'hold'. The company's market cap is approximately $741 million, with a P/E ratio of 13.90.

Company-level read

Ticker impact

$ODCNeutralMedium confidence
Context

Primary focus due to rating downgrade and financial performance

Expected impact

Moderate short-term decline expected, with potential stabilization if company fundamentals improve

Evidence & confidence

The rating change and recent insider activity suggest caution, but the company's valuation metrics and industry position could support a rebound if financials stabilize.

Market effects

Chemicals and specialty materials sectors may experience slight negative sentiment due to company-specific issues

Limited regional impact, primarily affecting US-based chemicals sector

Minimal, as company is a mid-cap with localized issues

Counterpoint

The downgrade may be overreacting; the company's core business remains stable, and the valuation could present a buying opportunity if the market overreacts

Key entities

  • Oil-Dri Corporation Of America

    Specialty chemicals company focusing on absorbent products.

Related articles

$ODCMed

Oil-Dri Corp of America (ODC): Results of Operations and Financial Condition

Oil-Dri Corp of America (ODC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 odcf26q3ex991-earningsrele.htm EX-99.1 Document 410 N. Michigan Ave. Chicago, Illinois 60611, U.S.A News Announcement For Immediate Release Exhibit 99.1 Oil-Dri Reports Record Third Quarter Revenues and Strong Earnings Growth CHICAGO-(June 8, 2026) - Oil-Dri Corporation

$CLMed

Piper Sandler cuts Colgate-Palmolive stock price target on cost pressures

Piper Sandler reduced its price target for Colgate-Palmolive (CL) to $95 from $98, citing cost pressures from elevated oil prices and inventory headwinds. The firm maintained an Overweight rating and a 2026 EPS estimate of $3.85, but lowered its 2027 EPS estimate to $4.12 from $4.23. CL trades at $87.47 with a P/E ratio of 34.6 and a gross profit margin of 60%. Other analysts have maintained positive outlooks, with RBC and UBS setting higher price targets.

$DYMed

KeyBanc raises Dycom Industries stock price target on growth outlook

KeyBanc raised its price target for Dycom Industries (NYSE:DY) to $429 from $423, citing growth outlook and meetings with management. The stock is down 48% from its 52-week high but is considered undervalued. Other analysts have mixed views, with UBS reiterating a Buy rating and Raymond James lowering its target. Dycom reported 38% revenue growth over the last year.

MedAI 8/10

85% of Nscale’s $103B of contracts are with Microsoft and Anthropic

Nscale revealed that 85% of its $103B contracts are with Microsoft (MSFT) and Anthropic, including $43.8B with MSFT and $44.6B with Anthropic. The company acknowledged concentration risk and reported a net loss of $1.02B on $140.6M sales for H1. Nvidia (NVDA) is a major shareholder and supplier. Nscale aims for a $35B valuation in its upcoming IPO.